Circle secured a $92.5 million funding round to push its cyclin D1 program ahead of its clinical lead, with preclinical combination data driving the funding priority. The company positioned CID-165 ahead of CID-078, targeting deeper breast cancer responses. The deal underscores continued investor appetite for cell-cycle and precision oncology approaches, particularly where combination rationale and biomarker-ready biology can be demonstrated before key clinical readouts. For portfolio planning, the funding also reflects the market’s preference for near-term escalation paths—moving from preclinical promise to first-in-human or expanded cohorts with clearer differentiation.